Quarterly ResultAug 13, 2026, 07:42 AM
Karyopharm Q2 Net Loss $67.0M; Myelofibrosis sNDA on Track; Liquidity Concern
AI Summary
Karyopharm Therapeutics reported a net loss of $67.0 million for Q2 2026, compared to $37.3 million in Q2 2025, on total revenue of $33.4 million. The company reaffirmed its full-year 2026 total revenue guidance of $130 million to $150 million. Karyopharm remains on track to submit its sNDA for selinexor in myelofibrosis in August, but its Phase 3 trial for endometrial cancer did not meet its primary endpoint. The company also disclosed liquidity concerns, stating that existing funds will last into September 2026, and a $15.8 million debt payment due in September could trigger a default without additional financing or a waiver.
Key Highlights
- Planned sNDA submission for selinexor in myelofibrosis in August under Accelerated Approval pathway.
- Q2 2026 Total Revenue was $33.4 million, down from $37.9 million in Q2 2025.
- Q2 2026 Net Loss was $67.0 million, compared to $37.3 million in Q2 2025.
- Q2 2026 Basic and Diluted Net Loss Per Share was $2.32, compared to $4.32 in Q2 2025.
- Full-year 2026 Total Revenue Guidance reaffirmed at $130 million to $150 million.
- Phase 3 XPORT-EC-042 trial for endometrial cancer did not meet its primary endpoint.
- Existing liquidity expected to fund operations only into September 2026.
- $15.8 million debt payment due September 10, 2026, poses default risk without financing.
Price Impact
More from KPTI